BioWorld

Aug. 7, 2007

Nektar Keeps Promotion Rights In $175M Deal On Amikacin Drug

Nektar Therapeutics Inc. is getting $50 million up front and retaining co-promotion rights in a deal with Bayer HealthCare AG covering its Phase II inhaled amikacin product for pneumonia. (BioWorld Today) Read More

BioCryst Adds $65M Privately To Boost Pipeline Development

Another TRP Family Member Charged With Causing Pain

Curis Raises $13 Million To Support Cancer Programs

Other News To Note

Clinic Roundup

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for Dec. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 12, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Illustration of brain with electrical activity background

ABS-1230 controls seizures in KCNT1-driven severe epilepsy

BioWorld Science

Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...

Illustration of head with maze that is missing parts

CTAD 2025: The challenges of combination therapies for dementia

BioWorld Science

At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...